George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.50
Bid: 103.00
Ask: 108.00
Change: -0.50 (-0.47%)
Spread: 5.00 (4.854%)
Open: 105.50
High: 105.00
Low: 105.00
Prev. Close: 105.50
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Long Term Incentive Plan

10 Oct 2022 08:00

RNS Number : 2584C
Intercede Group PLC
10 October 2022
 

Intercede Group PLC

("Intercede," "the Company" or the "Group'') 

Long Term Incentive Plan

Intercede, the leading specialist in digital identity, credential management and secure mobility, today announces that the Company's Remuneration Committee has adopted a revised long term incentive plan (the "LTIP") to align and incentivise Executive Board members to deliver growth and increased returns on investment and thereby create significant shareholder value for investors through share price performance.

The LTIP consists of two elements:

· grants of options ("Options") over ordinary shares of 1 pence in the Company ("Ordinary Shares") under a new Intercede Group plc Long Term Incentive Plan to the Executive management of the Company; and

· a growth share scheme (the "Growth Share Scheme"), the initial recipient of which is the Company's CEO, Klaas van der Leest.

Option grant

The Options have been granted at a price of 38 pence per Ordinary Share, being the average closing mid-market price of an Ordinary Share for the last three trading days ending 7 October 2022. The Options will be exercisable from 10 October 2025 to 9 October 2032, contingent on the 30-day average closing mid-market price of an Ordinary Share reaching at least 121 pence per Ordinary Share (the "Option Trigger Price") following the vesting period, being three years from the date of the grant (the "Performance Criteria") or such other earlier or later date or dates determined by the Company on or before the Date of Grant and specified in the Grant Letter and/or Option Certificate, subject always to the Option Trigger Price:

If the Performance Criteria above is achieved, the number of Options that will vest and become exercisable is as follows:

Name

Role

Number of Shares

Klaas van der Leest

CEO

500,000

Nitil Patel

CFO

500,000

 

The Growth Share Scheme

In the Growth Share Scheme, new shares in a subsidiary company, Intercede Limited, have been purchased at nominal cost and awarded to Klaas van der Leest as set out in the table below (the "Growth Shares").

The Growth Share Scheme will commence partial vesting if, in the 30-day period following the release of Company's results for the year ended 31 March 2025 (the "Vesting Period"), the average closing mid-market price of an Ordinary Share equals or exceeds 121 pence per Ordinary Share (the "Growth Share Scheme Trigger Price"), The Growth Shares do not carry any voting rights nor entitlement to any dividend. An initial allocation of 300 Growth Shares in Intercede Limited will be awarded under the Growth Share Scheme:

Director

Role

Growth Shares awarded

Maximum Ordinary Shares available under the Growth Share Scheme

Klaas van der Leest

CEO

300

1,785,705

 

Klaas van der Leest will be required to pay an amount of £7,500 on grant of the Growth Shares. This is linked to the tax market value of the Growth Shares at grant. No further amount is payable on vesting or settlement under the Scheme. It is anticipated that the Company will settle the Growth Share Scheme in Ordinary Shares of Intercede Group plc.

Performance criteria and vesting criteria

The number of Growth Shares exchangeable into Ordinary Shares depends on the average price of an Ordinary Share during the Vesting Period.

A 30-day averaging period will be used to measure the price of an Ordinary Share achieved to ensure that performance will not be unduly impacted by short-term volatility. The key components of the Growth Share Scheme can be adjusted for any dividend payments or capital adjustments which may occur as deemed fair by the Remuneration Committee.

The value of the Growth Shares is calculated by applying a 5% premium to the base share price of 66 pence ("Base Price"). The Base Price is based on the Company's average share price for the 30 days following the release of the Company's results for the year ended 31 March 2022.

· At 121 pence (an 83% per cent. increase from the Base Price) per Ordinary Share or below, no value is delivered to participants;

· At 173 pence (a 162% per cent. increase from the Base Price) per Ordinary Share, the Growth Share Scheme will be awarded in full; and

· Between 121 pence per Ordinary Share and 173 pence per Ordinary Share, the Growth Share Scheme award increases on a sliding scale up to the maximum award.

For the Growth Share Scheme to vest in full, the share price of the Company will need to increase by approximately 162% from the Base Price, representing an increase in market capitalisation of approximately £101m.

Participants have 60 days following the Vesting Period to exchange the Growth Shares into Ordinary Shares. Any Growth Shares outstanding on the long stop date (being 60 days after the Company's results for the year ended 31 March 2025 are announced) will automatically be converted to deferred shares. Deferred shares have no rights and no entitlement to capital in the Company.

Earlier conditional vesting of Growth Shares could occur if the holder ceases employment on good leaver terms as detailed within the Growth Share Scheme or if the Remuneration Committee considered it appropriate, on the occurrence of a change of control or another major corporate event. 

At their absolute discretion, the Remuneration Committee may make further grants to new participants under the Growth Share Scheme.

In the preparation of the Growth Share Scheme, the input of a number of the Company's key shareholders has been sought.

Related Party Transaction

The grant of the Growth Shares to Klaas van der Leest comprises a related party transaction under Rule 13 of the AIM Rules for Companies. The independent directors of Intercede, which for the purposes of this related party transaction comprise all board members other than Klaas van der Leest, consider, having consulted with Intercede's nominated adviser, that the terms of the transaction are fair and reasonable insofar as Intercede's shareholders are concerned.

Total options outstanding

Following the grant of Options and the Growth Shares (assumes maximum award), the Company has a total of 4,065,705 options over Ordinary Shares outstanding, and by including SIPP shares, it represents approximately 8.6 per cent. of the Company's issued share capital.

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

 

 

finnCap Ltd

Tel. + 44 (0)20 7220 0500

Simon Hicks/Fergus Sullivan

Corporate Finance

Tim Redfern/Charlotte Sutcliffe

ECM

 

About Intercede

Intercede is a cybersecurity company specialising in digital identities, derived credentials and access control, enabling digital trust in a mobile world.

Headquartered in the UK, with offices in the US, we believe in a connected world in which people and technology are free to exchange information securely, and complex insecure passwords become a thing of the past.

Our vision is to make the highest levels of cybersecurity available to organisations and consumers alike, solving complexity and scalability issues by managing high volumes of digital credentials.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Klaas van der Leest

2.

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intercede Group plc

 

b)

LEI

213800VFMNCYCDQ65C90

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Options over Ordinary Shares

Identification code

GB0003287249

b)

Nature of the transactions

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

38p

500,000

d)

Aggregated information:

· Aggregated volumes

· Prices

See 4(c) above

e)

Date of the transaction

10 October 2022

 

f)

Place of the transaction

Outside of a trading venue

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nitil Patel

2.

Reason for the Notification

a)

Position/status

CFO

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intercede Group plc

 

b)

LEI

213800VFMNCYCDQ65C90

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Options over Ordinary Shares

Identification code

GB0003287249

b)

Nature of the transactions

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

38p

500,000

d)

Aggregated information:

· Aggregated volumes

· Prices

See 4(c) above

e)

Date of the transaction

10 October 2022

 

f)

Place of the transaction

Outside of a trading venue

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Klaas van der Leest

2.

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intercede Group plc

 

b)

LEI

213800VFMNCYCDQ65C90

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Growth share scheme shares in Intercede Limited, which may be converted into new ordinary shares in Intercede Group plc

Identification code

GB0003287249

b)

Nature of the transactions

Grant of growth share scheme shares in Intercede Limited, which may be converted into new ordinary shares in Intercede Group plc

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£25

300

d)

Aggregated information:

· Aggregated volumes

· Prices

See 4(c) above

e)

Date of the transaction

10 October 2022

 

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSAFUUEESEDS
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.